Table: Jcr Pharmaceuticals - 9-MTH group results
28/01/2026 08:00
Jan 28 (Reuters)-
Jcr Pharmaceuticals Co., Ltd.
CONSOLIDATED FINANCIAL HIGHLIGHTS
(in billions of yen unless specified)
9 months ended 9 months ended Year to
Dec 31, 2025 Dec 31, 2024 Mar 31, 2026
LATEST YEAR-AGO LATEST
RESULTS RESULTS FORECAST
Sales 30.35 25.88 39.50
(+17.3 pct) (-23.2 pct) (+19.4 pct)
Operating 427 mln loss 754 mln 400 mln
Recurring 711 mln loss 1.38 400 mln
Net 1.74 loss 576 mln 1.60
EPS 14.30 yen loss 4.63 yen 13.12 yen
EPS Diluted 14.30 yen
Ann Div 20.00 yen 20.00 yen
-Q2 div 10.00 yen 10.00 yen
-Q4 div 10.00 yen 10.00 yen
NOTE - Jcr Pharmaceuticals Co., Ltd..
To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4552.T
Recent news on JCR Pharmaceuticals
See all newsBrief: JCR Pharmaceuticals Receives Marketing Authorization In Kuwait For Izcargo
Italfarmaco And Jcr Pharmaceuticals Enter Into Exclusive License Agreement For Jr-141 In United States, Europe, And Latin America
Brief: Jcr Pharmaceuticals Receives Orphan Drug Designation For Givinostat In Japan
Brief: Medipal & JCR Dose First Patient In Global Phase I/II Trial OF JR-446 For Mucopolysaccharidosis Type IIIB
Table: Jcr Pharmaceuticals -Q1 group results